Clinical Trials in Chicago

Showing 1461-1480 of 17,609 trials

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

NCT06446661

The purpose of this section is to learn how text message reminders might help with regularly taking chemotherapy medications for Adolescents and Adults with Acute Lymphoblastic leukemia (ALL).

Acute Lymphoblastic Leukemia

University of Chicago38 participantsStarted Dec 2026

Chicago, Illinois, United States

RECRUITINGPhase 22.2 miles

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

NCT07065630

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .

Head and Neck CancerHPV

University of Chicago38 participantsStarted Oct 2025

Chicago, Illinois, United States

RECRUITINGPhase 22.2 miles

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation

Alliance for Clinical Trials in Oncology124 participantsStarted Sep 2015

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +774 more locations

Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Find Trials by Condition in Chicago

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

An Observational Study of Patients With Chronic Liver Disease

Conduction System Pacing International Registry (CONSPIRE)

Persona IQ Cohort Study

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

Distance-Based Exercise to Preserve Function and Prevent Disability

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors